Sandoz Begins Independent Trade on SIX Swiss, Promises Growth in Generics

Sandoz launches as an independent entity on the SIX Swiss Exchange, equipped with a robust credit profile and a bright growth trajectory in the generics and biosimilars industry.

Dawn of a New Era

The separation from former parent company Novartis marks a new era for Sandoz, the global leader in generic and biosimilar medicines. Chairman Gilbert Ghostine emphasized that while the company is independent, its purpose remains unchanged: pioneering access to quality medicines for patients worldwide, Korea Bizwire reported.

According to the Sandoz website, CEO Richard Saynor outlined six strategic levers driving the company's long-term value during the Sandoz Capital Markets Day. These include capitalizing on market fundamentals, maintaining leadership and scale, pursuing multiple growth drivers, improving margins, accelerating cash generation, and nurturing a compelling sustainability story.

Unwavering Commitment to Pioneering Access

Sandoz actively shapes the global healthcare environment by delivering significant annual savings of over USD 17 billion in Europe and the US alone. With a strong presence in over 100 countries, the company reaches approximately 500 million patients annually, generating an estimated total social impact of USD 180 billion annually.

As an independent company, Sandoz is fully enabled to execute its purpose-driven strategy. Focused on sustainable leadership within the generics and biosimilars industry, Sandoz is poised to make an even greater impact on global healthcare systems.

Accelerating Profitable Growth

Sandoz is well-positioned for continued profitable growth with its inclusion in market indices and investment-grade credit rating. The company's commitment to innovation, quality, and accessibility ensures its role as a global leader and European champion in the generic and biosimilar medicines sector.

Sandoz's dedication to making quality medicines available to more people in more places exemplifies its pursuit of novel delivery methods. By leveraging technology and innovation, the company aims to expand access and address unmet healthcare needs on a global scale.

Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost. Despite strong competitive pressures, the industry is set to grow steadily over the next decade, driven by underlying demand for these system-critical medicines.

Photo: Online Marketing/Unsplash